Last edition
News about "IASO Biotherapeutics "
IASO Bio Gets Approval of New Drug Application for Equecabtagene Autoleucel
Equecabtagene Autoleucel (FUCASO) was approved by China's National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent.
IASO Biotherapeutics | 31/03/2025 | By Aishwarya
IASO Bio Receives Hong Kong's DOH Acceptance of NDA for Equecabtagene Autoleucel
This treatment is indicated for patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received three or more prior lines of therapies.
IASO Biotherapeutics | 17/02/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy